Navigation Links
Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008

CAMBRIDGE, Mass., June 24 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Tolerx was determined to be one of the "fiercest," proven by its creativity and innovations in the industry.

An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.

John Carroll, Editor of FierceBiotech, said, "A rich partnership pact with GlaxoSmithKline last October kept Tolerx in the race to develop an anti-CD3 monoclonal antibody for autoimmune disease. That program has now begun a Phase III clinical trial known as DEFEND, and all the chips are on the table."

"FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. "Being selected as a member of the 'Fierce 15' is an honor that highlights Tolerx's potential to make a significant impact in the biotech market."

The Fierce 15 celebrates the spirit of being "fierce" -- championing innovation and creativity, even in the face of intense competition. The complete list of 'Fierce 15' companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development for the potential treatment of various autoimmune indications: otelixizumab, an anti-CD3 MAb which is being developed in collaboration with GlaxoSmithKline and a modified form of TRX1, which is being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new product candidates that circumvent immune system tolerance. These product candidates are being evaluated for the treatment of cancer or chronic viral diseases. For more information, please visit

Tolerx Forward-Looking Statements

This press release contains certain statements that include the word "potential". Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding outcomes sought to be realized in the clinical trials or preclinical development, and the potential for Tolerx to make a significant impact in the biotech market are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There can be no certainty that Tolerx will advance any clinical candidate or other component of its pipeline to the clinic, to the next regulatory step or to commercialization or that Tolerx will ever realize revenue from commercialization of product candidates it is currently or may in the future seek to develop. Factors and risks that may impact management's expectations and affect the forward-looking statements include but are not be limited to the sufficiency, scope and breath of the company's vision, the strength of the company's technology, the continuation, robustness and resilience of the company's innovation and creativity, results of DEFEND and other future clinical studies, results of pre-clinical studies, the ability to obtain regulatory approval for advancement of any product candidate, the continuation of the collaborations with GSK and Genentech, the introduction of competing therapies by other companies and changes in the company's business plan or objectives. These statements reflect the view of Tolerx as of the date of this press release and should not be relied upon as reflecting the company's views at any date subsequent to this release. Tolerx undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
2. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
3. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
4. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
5. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
6. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
7. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
8. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
9. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
10. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):